Search for other works by this author on: ...

T-cell activation involves two phases, enabling a more precise immune response. This insight may boost cancer immunotherapy ...

QRICH1 could slow down the activation of T cells, Pomerantz says. For the new study, the scientists first genetically engineered mice to lack the QRICH1 protein, and conducted experiments ...

More information: Nicole M. Carter et al, QRICH1 mediates an intracellular checkpoint for CD8 + T cell activation via the CARD11 signalosome, Science Immunology (2025). DOI: 10.1126/sciimmunol.adn8715 ...

mice in which Tet1/3 were ablated during T-cell development and mature CD8 T cells, respectively, we show that Tet1/3 regulates these cell fates by licensing the chromatin landscape of genes ...

Distinct proteolytic pathways share convergent activation patterns in many pathological contexts. Two new studies in Nature report on how effector memory-like CD8 + T cells infiltrate inflamed ...

By contrast, CD8 T cells will proliferate and activate in response to HIV infection, but this response tends to attenuate over time. The CD4/CD8 ratio tends to decrease as we age, making people more ...

Compromised antigen presentation ranks among the top mechanisms that render cancers non-immunogenic (non-responsive to immune ...

A team from the Max Planck Research Group for Systems Immunology at the University of Würzburg has identified a previously unknown phase of the immune response. The results, published in Science, ...

The University of Texas MD Anderson Cancer Center, Houston, TX.